Genital HerpesHerpesGNCT05675228
Knowledge of Young Adults About Genital Herpes
An observational study of Genital Herpes, run by Université de Reims Champagne-Ardenne at 1 site in France.
Trial summary
Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection. Read more about this study
- Who is it for?
- Ages 25 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Genital Herpes
- What is being tested?
- data collection
- How many people
- 2,000 participants
- Where
- 1 siteFrance
- Study dates
- 2 Dec 2022to 1 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: men and women aged 25 to 35, having sex or not and agreeing to participate in the study.
Who may be able to join
- Men and women
- Aged 25 to 35
- Having sex or not
- Agreeing to participate in the study
Who cannot join
- Not agreeing to participate in this study
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Fanny Bichon
Reims, 51100
Fanny Bichon, 0326918822 ext. +33, fanny.bichon2@orange.fr
About this study
Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection.
Read the detailed description
the aim of the study is to describe knowledge of adults aged 25 to 35 about genital herpes (symptoms, transmission, prevention).
- Conditions
- Genital Herpes
- Being tested
- data collection
- Keywords
- Knowledge, Young adults, genital herpes
- Medical subject headings
- Herpes Genitalis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collectionOther
Knowledge about genital herpes
| Study group | Role | What they receive |
|---|---|---|
| young adults | men and women aged 25 to 35 Receives: Other: data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
transmission
Modes of transmission of genital herpes (public toilets, home textiles, sexual transmission)
Measured: Day 0
symptoms
Types of symptoms of genital herpes (no symptom, rash, fever)
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2023
- Study start2 Dec 2022
- Primary completion1 Apr 2023 (estimated)
- Study completion1 Jul 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Genital HerpesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université de Reims Champagne-Ardenne
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05675228
- Sponsor's protocol ID
- 2022_RIPH_016_HerpesG
- Acronym
- HerpesG
- Status last verified
- Dec 2022
- First submitted
- 29 Dec 2022
- Last updated
- 9 Jan 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Knowledge of Young Adults About Genital Herpes
- ClinicalTrials.gov ID
- NCT05675228
- Acronym / sponsor ID
- HerpesG / 2022_RIPH_016_HerpesG
- Conditions
- Genital Herpes
- Keywords
- Knowledge, Young adults, genital herpes
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Université de Reims Champagne-ArdenneUniversity, hospital or other
- Study start
- 2 Dec 2022 (actual)
- Primary completion
- 1 Apr 2023 (estimated)
- Study completion
- 1 Jul 2023 (estimated)
- First posted
- 9 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection.
Detailed description
the aim of the study is to describe knowledge of adults aged 25 to 35 about genital herpes (symptoms, transmission, prevention).
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| young adults | – | Other: data collectionmen and women aged 25 to 35 |
Who may qualify
- Ages
- 25 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- men and women aged 25 to 35, having sex or not and agreeing to participate in the study.
Key inclusion criteria (4 listed)
- Men and women
- Aged 25 to 35
- Having sex or not
- Agreeing to participate in the study
Key exclusion criteria (1 listed)
- Not agreeing to participate in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collectionKnowledge about genital herpes | Other | young adults |
Primary outcome
transmission
Time frame: Day 0
Modes of transmission of genital herpes (public toilets, home textiles, sexual transmission)
symptoms
Time frame: Day 0
Types of symptoms of genital herpes (no symptom, rash, fever)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2023.
Related trials for Genital Herpes
Not yet recruitingPhase 2
Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes
HSV-2 Infection
Active, not recruitingPhase 2
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
Lymphoproliferative Disorder, HHV-8
Active, not recruitingPhase 1
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
Genital Herpes Simplex Type 2
RecruitingObservational study
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Human Immunodeficiency Virus, Castleman's Disease
Enrolling by invitationPhase 1
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
Genital Herpes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Genital Herpes, run by Université de Reims Champagne-Ardenne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
transmission (time frame: Day 0). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2023.